Saghmos Therapeutics Announces Participation in the Evercore ISI 2024 Emerging Private Biotech Conference

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company focused on the prevention and treatment of cardiorenal complications, announced its participation in the 2024 Emerging Private Biotech Conference hosted by Evercore ISI.

Anna Kazanchyan, MD, Saghmos' Founder and Chief Executive Officer, is scheduled for a Fireside Chat session on Wednesday, February 28^th from 1:05pm to 1:35pm Eastern Time. A live webcast of the session will be accessible at https://wsw.com/webcast/evercore40/sagh/2338909. A replay of the webcast will be posted shortly after the call.

Saghmos recently announced the appointment of pharmaceutical industry veteran Fred Hassan as Chairman of the Board of Directors. Saghmos also announced the appointment of Dr. Stephen Grant, former Deputy Director, Division of Cardiology and Nephrology at the FDA, as Chief Regulatory Officer.

About Saghmos Therapeutics

Saghmos is developing ST-62516 (trimetazidine), a cardiorenal metabolic modulator to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as PCI. Saghmos' IND for ST-62516 was cleared by the FDA in 2023. Over one million PCI procedures are performed annually in the US in patients with unstable angina (heart attack). About half of these patients have comorbidities which impact the safety of PCI. This is a major unmet medical need with no FDA-approved drugs available to prevent or treat AKI and MACKE.

Saghmos Therapeutics has an issued US patent (Patent number 11,123,345) for the prevention and treatment of acute kidney injury after contrast procedures and has received Notice of Allowance for a second US patent.

Forward looking statements

This press release contains forward-looking statements, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Saghmos Therapeutics' business, intellectual property, clinical and regulatory plans, commercial potential, and the value and benefits of ST-62516. In any forward-looking statement in which Saghmos expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Saghmos' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources, uncertainties and changes related to the law and regulatory process, and general changes in the economic environment. These forward-looking statements are based on our current expectations. Saghmos does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.